PROTAC AR-NTD antagonist 1 (compound 18) is a small molecule belonging to the protein-targeting chimeras (PROTACs) that selectively targets the N-terminal domain (AR-NTD) of the Androgen Receptor variant AR-V7. By antagonizing AR-NTD, this compound effectively degrades AR-V7 protein and triggers apoptosis in prostate cancer (PC) cells, with degradation efficiencies in VCaP cells recorded at 62.2% (1 μM) and 71.1% (5 μM), as noted in reference [1].